Clinical trial of ototopical ofloxacin for treatment of chronic suppurative otitis media

Clinical Therapeutics

Volumn 20, Issue 4, 1998, Pages 744-759

  Agro, Angelo S ^a   Garner, Eric T ^b   Wright III, J William ^c   De Escobar, Irma Caballeros ^d   Villeda, Byron ^e   Seidlin, Mindell ^f  

^a Prof Otolaryngology Associates   (United States)

^b Advanced Clinical Research   (United States)

^c Physicians Research Group   (United States)

^d Social Secty Institute of Guatemala   (Guatemala)

^e Hospital Rodolfo Robles   (Guatemala)

^f Daiichi Pharmaceutical Corporation   (United States)

Author keywords

Chronic suppurative otitis media; Ofloxacin; Otorrhea; Tympanic membrane

Indexed keywords

EAR DROPS; OFLOXACIN;

ADOLESCENT; ADULT; ARTICLE; BACTERIUM ISOLATION; CHRONIC OTITIS MEDIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EARDRUM PERFORATION; ERADICATION THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; TASTE DISORDER; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0031666663     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80137-9     Document Type: Article

References (16)

1. Kenna MA. Treatment of chronic suppurative otitis media. Pediatr Otol. 1994;27: 457-472.
2. Nelson JD. Chronic suppurative otitis media. Pediatr Infect Dis J. 1988;7:446-448.
3. Yuen PW, Lau SK, Chau PY, et al. Ofloxacin eardrop treatment for active chronic suppurative otitis media: Prospective randomized study. Am J Otol. 1994; 15:670-673.
4. Browning GG, Gatehouse S, Calder IT. Medical management of active chronic otitis media: A controlled study. J Laryngol Otol. 1988;102:491-495.
5. Supiyaphun P, Tonsakulrungruang K, Chochaipanichnon L, et al. The treatment of chronic suppurative otitis media and otitis externa with 0.3 per cent ofloxacin otic solution: A clinico-microbiologic study. J Med Assoc Thailand. 1995;78: 18-21.
6. Wong DLH, Rutka JA. Do aminoglycoside otic preparations cause ototoxicity in the presence of tympanic membrane perforations? Otolaryngol Head Neck Surg. 1997;116:404-410.
7. Pickett BP, Shinn JB, Smith MFW. Ear drop ototoxicity: Reality or myth? Am J Otol. 1977;18:782-789.
8. Tong MC, Woo JKS, van Hasselt CA. A double-blind comparative study of ofloxacin otic drops versus neomycin-polymyxin B-hydrocortisone otic drops in the medical treatment of chronic suppurative otitis media. J Laryngol Otol. 1996; 110:309-314.
9. Podoshin L, Fradis M, Ben David J. Ototoxicity of ear drops in patients suffering from chronic otitis media. J Laryngol Otol. 1989;103:46-50.
10. Neu H, Chin N. In vitro activity of s-ofloxacin. Antimicrob Agents Chemother. 1989;33:1105-1107.
11. Peterson L, Cooper I, Willard K, et al. Activity of twenty-one antimicrobial agents including l-ofloxacin against quinolone-sensitive and -resistant, and methicillin-sensitive and -resistant Staphylococcus aureus. Chemotherapy. 1994;40:21-25.
12. Oh J, Paek K, Ahn M, Kim M, et al. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone. Antimicrob Agents Chemother. 1996;40:1564-1568.
13. Data on file. Daiichi Pharmaceutical Corporation, Fort Lee, New Jersey, 1996.
14. Barlow DW, Duckert LG, Krieg CS, Gates GA. Ototoxicity of topical otomicrobial agents. Acta Otolaryngol (Stockh). 1995; 115:231-235.
15. Jahn AS, Hawke M. Infections of the external ear. In: Cummings CW, Fredrickson JM, Harker LA, et al, eds. Otolaryngology - Head and Neck Surgery. 2nd ed. St. Louis, Mo: Mosby Year Book; 1993: 2788-2794.
16. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved standard M7-A3. Wayne, Pa: National Committee for Clinical Laboratory Standards; 1993.